115 related articles for article (PubMed ID: 7014599)
1. Discrepant performance on oral and intravenous glucose tolerance tests: the role of gastric inhibitory polypeptide.
Elahi D; Andersen DK; Tobin JD; Andres R
J Clin Endocrinol Metab; 1981 Jun; 52(6):1199-203. PubMed ID: 7014599
[TBL] [Abstract][Full Text] [Related]
2. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric inhibitory polypeptide.
McCullough AJ; Miller LJ; Service FJ; Go VL
J Clin Endocrinol Metab; 1983 Feb; 56(2):234-41. PubMed ID: 6337173
[TBL] [Abstract][Full Text] [Related]
3. Gastric inhibitory polypeptide and insulin: response to intraduodenal and intravenous glucose infusions in fetal and neonatal pigs.
Kühl C; Hornnes PJ; Jensen SL; Lauritsen KB
Endocrinology; 1980 Nov; 107(5):1446-50. PubMed ID: 7000494
[TBL] [Abstract][Full Text] [Related]
4. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.
Andersen DK; Elahi D; Brown JC; Tobin JD; Andres R
J Clin Invest; 1978 Jul; 62(1):152-61. PubMed ID: 659629
[TBL] [Abstract][Full Text] [Related]
5. Disparity between glucose-dependent insulinotropic polypeptide and insulin responses in obese man.
Sarson DL; Kopelman PG; Besterman HS; Pilkington TR; Bloom SR
Diabetologia; 1983 Nov; 25(5):386-91. PubMed ID: 6360777
[TBL] [Abstract][Full Text] [Related]
6. Gastric inhibitory polypeptide (GIP) and insulin release in response to oral and intravenous glucose in uremic patients.
Lauritzen JB; Lauritsen KB; Olsen ME; Timmerman I
Metabolism; 1982 Nov; 31(11):1096-9. PubMed ID: 6752641
[TBL] [Abstract][Full Text] [Related]
7. Glucose-induced GIP levels in patients with insulinoma.
Tamburrano G; Lala A; Mauceri M; Leonetti F; Andreani D
Horm Metab Res; 1984 Dec; 16 Suppl 1():200-3. PubMed ID: 6099816
[TBL] [Abstract][Full Text] [Related]
8. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
9. Gastric inhibitory polypeptide responses and glucose turnover rates after natural meals in type II diabetic patients.
Osei K; Falko JM; O'Dorisio TM; Fields PG; Bossetti B
J Clin Endocrinol Metab; 1986 Feb; 62(2):325-30. PubMed ID: 3510224
[TBL] [Abstract][Full Text] [Related]
10. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity.
Salera M; Giacomoni P; Pironi L; Cornia G; Capelli M; Marini A; Benfenati F; Miglioli M; Barbara L
J Clin Endocrinol Metab; 1982 Aug; 55(2):329-36. PubMed ID: 7045154
[TBL] [Abstract][Full Text] [Related]
11. Gastric inhibitory polypeptide (GIP) response to an oral glucose load in the patients with diabetes mellitus.
Nakanome C; Akai H; Umezu M; Toyota T; Goto Y
Tohoku J Exp Med; 1983 Mar; 139(3):287-92. PubMed ID: 6344327
[TBL] [Abstract][Full Text] [Related]
12. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
Nauck MA; Siemsglüss J; Orskov C; Holst JJ
Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
[TBL] [Abstract][Full Text] [Related]
13. The response of gastric inhibitory polypeptide (GIP) and insulin to glucose in duodenal ulcer patients.
Lauritsen KB; Moody AJ
Diabetologia; 1978 Mar; 14(3):149-53. PubMed ID: 658630
[TBL] [Abstract][Full Text] [Related]
14. The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus.
Elahi D; Andersen DK; Muller DC; Tobin JD; Brown JC; Andres R
Diabetes; 1984 Oct; 33(10):950-7. PubMed ID: 6383904
[TBL] [Abstract][Full Text] [Related]
15. The correlation between gastric emptying time and the response of GIP and enteroglucagon to oral glucose in duodenal ulcer patients.
Lauritsen KB; Frederiksen HJ; Uhrenholdt A; Holst JJ
Scand J Gastroenterol; 1982 Jun; 17(4):513-6. PubMed ID: 6753108
[TBL] [Abstract][Full Text] [Related]
16. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects.
Ross SA; Dupre J
Diabetes; 1978 Mar; 27(3):327-33. PubMed ID: 640238
[TBL] [Abstract][Full Text] [Related]
17. Gastric inhibitory polypeptide response to hyper- and hypoglycemia in insulin-dependent diabetics.
Reynolds C; Tronsgard N; Gibbons E; Blix PM; Rubenstein AH
J Clin Endocrinol Metab; 1979 Aug; 49(2):255-61. PubMed ID: 457845
[TBL] [Abstract][Full Text] [Related]
18. The incretin effect does not differ in trained and untrained, young, healthy men.
Lund MT; Dalby S; Hartmann B; Helge J; Holst JJ; Dela F
Acta Physiol (Oxf); 2014 Mar; 210(3):565-72. PubMed ID: 24354574
[TBL] [Abstract][Full Text] [Related]
19. Serum gastric inhibitory polypeptide (GIP) in duodenal ulcer disease: relationship to glucose tolerance, insulin, and gastrin release.
Arnold R; Creutzfeldt W; Ebert R; Becker HD; Börger HW; Schafmayer A
Scand J Gastroenterol; 1978; 13(1):41-7. PubMed ID: 635445
[TBL] [Abstract][Full Text] [Related]
20. Gastric inhibitory polypeptide (GIP) in maturity-onset diabetes mellitus.
Crockett SE; Mazzaferri EL; Cataland S
Diabetes; 1976 Oct; 25(10):931-5. PubMed ID: 976601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
